Bristol Myers Squibb Taps BioArctic’s Brain Transporter Tech After $500M Lekembi Sales
Bristol Myers Squibb gains access to BioArctic AB’s evolving brain transporter technology after BioArctic recorded its strongest annual results ever, with Lekembi sales exceeding $500 million and approvals in 53 countries. Lingering European reimbursement challenges and currency headwinds could affect future royalty income from this collaboration.
1. Partnership Details
Bristol Myers Squibb is among BioArctic’s major pharmaceutical partners, securing access to its brain transporter technology to develop antibody-based neurological therapies under joint research agreements. Specific financial terms and project milestones remain undisclosed.
2. BioArctic’s Record 2025 Performance
BioArctic delivered record financial results in 2025 driven by portfolio expansion into Parkinson’s and Huntington’s programs and global collaboration revenues, marking its strongest annual growth with Lekembi sales exceeding $500 million across 53 markets.
3. Impact on BMY’s Pipeline
Through this collaboration, Bristol Myers Squibb is positioned to leverage BioArctic’s brain transporter platform for internal neurology programs, potentially accelerating clinical candidates such as alpha synuclein antibodies toward first-in-human trials within two years post-nomination.
4. European Reimbursement Headwinds
Lekembi adoption in Europe lags due to ongoing reimbursement negotiations in several countries and a negative cost-effectiveness recommendation in Denmark, which could delay downstream royalty and milestone payments to Bristol Myers Squibb.